Amicus Therapeutics – Leading Biotechnology Firm Based in the United States

Amicus Therapeutics is a publicly traded firm biopharmaceutical company headquartered in Cranbury, New Jersey. Before the company went public, it was funded by a host of different venture capital firms like Radius Ventures, New Enterprise Associates, and Canaan Partners. The focus of Amicus Therapeutics is on rare and orphan diseases, particularly the set of disorders collectively known as the lysosomal storage disorders. The platform that the company adheres to in its development is Chaperone-Advanced Replacement Therapy, also referred to as CHART. Amicus Therapeutics is focused on the development of enzyme replacement therapies as well through its product development platform. Presently, Amicus Therapeutics doesn’t manufacture but rely on contract manufacturing.

https://www.crunchbase.com/organization/amicus-therapeutics

The company previously had just one research site in New Jersey, but in 2008, the company opened its second research base in San Diego. The company was funded by the Michael J Fox Foundation and the David Geffen School of Medicine at UCLA in the year 2010 and received a grant from the former organization of $500,000 (GoogleFinance). The Alzheimer’s Drug Discovery Foundation also provided the grant of $210,000 in 2010. As the world of medicine continues to improve and expand, it is essential for the biotechnology firms to do their part and devise ways to find a cure for the diseases that are making the lives of millions of kids and adults miserable across the globe. The biotechnology companies are equipped with the knowledge and the tools as well as the expertise needed to find ways to cure and control various rare and orphan diseases, which is what the Amicus Therapeutics is doing.

 

The principal product provided by Amicus Therapeutics is Migalastat, which is used to treat people who are in the later stage of suffering from Fabry disease. Amicus Therapeutics understands that science plays a huge role in transforming the field of medicine and ensures that it continues to develop therapies that help in treating rare and orphan diseases. Some of the diseases that Amicus Therapeutics is active working on to find its cure are Fabry Diseases, Pompe Disease, genetic connective skin disorder, and Lysosomal Storage Disorder. The company continues to make massive investments in research and development to strengthen and advance its research-based activities.

 

Check out Amicus Therapeutics on Twitter

Introducing Oncotarget To All

Past few years have been witness to a vast accumulation of knowledge on oncogenes, cellular processes, oncoproteins, tumor suppressors, cellular responses, signal transduction, intercellular interactions along with the function as well as dysfunction of cells, organs, and other systems. In fact, it is the therapeutic targeting of all these molecules as well as processes that have become a growing area in the field of cancer research. This field is becoming increasingly complex as well as multidisciplinary. Hence now the knowledge has to move from basic research and reach the clinic. This would encompass varied fields that would include cell biology, molecular biology, pharmacology, as well as pathology, physiology, oncology and so much more.

Read more https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

Even in many other medical disciplines, new therapy targets have been identified. The agents that have been developed for specific diseases can be used in treating cancer. This can be applied vice versa too. There are some drugs being used for treating infections and such other disorders. These can impact targets that are relevant to cancer too. Download output styles at Endnote.com.

This is the right time for a new journal that will be specifically focused on cancer-relevant targets. It will have to encompass the complexity of this vast field.

Several of the inaugural issues of Oncotarget feature papers on basic, besides translational as well as clinical research. Next are the paradigm-shifting articles. Besides, there would be systematic reviews, along with opinions as well as perspectives coming in from eminent personalities. This way it has a unique as well as broad scope. Oncotarget is offering several other unique features too. Hence it is going to be a high impact journal that is going to make a mark in the twenty-first century.

There are many drugs that can be particularly attractive as anti-cancer agents as they have been approved for clinical use. Hence their effects, as well as side effects, are already known. The anti-malarial, as well as anti-epileptic drugs, are considered as anti-cancer drugs. Now some anti-cancer drugs are also being indicated for atherosclerosis and even aging. Hence oncotarget is going to encompass research on molecules, pathways, as well as cellular functions, cell types along with tissues that can be targeted which are relevant to cancer along with other diseases. Oncotarget is also available on Dove Press.